Advertisement

Topics

Chiltern acquisition improves competitiveness of offerings, says Covance CEO

14:06 EDT 31 Jul 2017 | Outsourcing-Pharma

Original Article: Chiltern acquisition improves competitiveness of offerings, says Covance CEO

NEXT ARTICLE

More From BioPortfolio on "Chiltern acquisition improves competitiveness of offerings, says Covance CEO"

Quick Search
Advertisement
 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...